Ireland–US Trade in 2025: $133.5 Billion, Concentrated, Tariff-Shaped
Full-year USITC DataWeb analysis of the product categories, customs district routing, corporate drivers and monthly pattern that defined a record year.
Ireland, 2025
growth 2024–2025
alone in 2025
total 2025 flow
Full-year 2025 US customs data from the USITC DataWeb shows US imports from Ireland reached $133.5 billion – a 29% increase on 2024 and a 62% increase on 2023. The concentration of that trade in a handful of pharmaceutical product categories, a single US customs district, and a small set of multinational manufacturers defines the structural shape of the Ireland–US goods relationship today. The monthly cadence through 2025, dominated by a March spike and an autumn surge driven by tariff timing, is as significant as the annual total.
Scope of the analysis
All figures refer to General Customs Value of physical goods imported into the United States, sourced from USITC DataWeb. The dataset does not include IT services, software, digital services, intellectual property flows or financial services. Ireland’s overall economic relationship with the United States is far broader than goods exports: Services, IP and corporate-tax-related flows are substantial. Within the specific channel of physical goods imports, however, pharmaceuticals are overwhelmingly dominant.
All figures are nominal (current US dollar) General Customs Value. Inflation is not removed. Even so, the 2024–2025 acceleration far exceeds US price inflation over the same period.
The scale of trade acceleration
From $82.4 billion in 2023 to $103.3 billion in 2024 to $133.5 billion in 2025 – a 62% two-year surge driven overwhelmingly by pharmaceuticals and biologics. The pace of acceleration has itself accelerated: 25.3% growth in 2023–2024 was followed by 29.3% growth in 2024–2025.
Source: USITC DataWeb. Exact values (USD billions): 2020 $66.05, 2021 $73.88, 2022 $82.64, 2023 $82.42, 2024 $103.28, 2025 $133.54.
The monthly pattern: A tariff-shaped year
Annual totals hide what turned out to be the most consequential feature of 2025: A highly uneven monthly cadence driven by pharmaceutical importers front-loading shipments ahead of anticipated US tariff action. The 2024 pattern is relatively smooth; the 2025 pattern is not.
Source: USITC DataWeb, monthly general customs value. 2025 exact values (USD billions): Jan $13.64, Feb $15.27, Mar $30.73, Apr $10.87, May $13.41, Jun $6.66, Jul $4.30, Aug $5.18, Sep $19.94, Oct $4.97, Nov $4.75, Dec $3.83.
Three features stand out:
- March 2025: $30.7 billion in a single month. This is larger than the full-year total of US imports from Ireland in every year before 2009, and more than double the next largest month ever recorded. It reflects a massive pre-positioning of finished dose and hormone products in the US ahead of anticipated Section 232 pharmaceutical tariffs.
- Q1 front-loading: January, February and March 2025 together accounted for $59.6 billion – 45% of the full-year total compressed into the first quarter. The same three months in 2024 totalled $21.7 billion.
- The September pulse: After a collapse in June–August (combined $16.1B, less than any single spring month), September rebounded to $19.9 billion. This aligns closely with the 21 August 2025 EU–US joint statement capping pharmaceutical tariffs at 15%, which gave importers clarity and triggered a second wave of shipments before later policy deadlines.
The December 2025 figure of $3.8 billion is the lowest monthly value since February 2019. January 2026 came in at $3.9 billion (per US Census Bureau preliminary data), consistent with a continued post-stockpile wind-down rather than a normalised baseline. The 2025 annual total of $133.5 billion is real – the goods physically crossed the US customs border – but it reflects accelerated timing as well as underlying demand growth.
What is being imported: The product composition
The 2025 goods composition is dominated by life sciences. The top three HTS 4-digit headings accounted for $98.5 billion of the $133.5 billion total – roughly three-quarters of the trade, in three headings. HTS 2937 (hormones, including GLP-1 analogues) alone reached $56.3 billion, or about 42% of the total.
Source: USITC DataWeb, full-year 2025. Exact values (USD billions): 2937 $56.30, 3002 $28.57, 3004 $13.58, 9801 $6.15, 9021 $5.63, 2934 $4.46, 2933 $3.72, 9018 $3.49, 3302 $2.39, 8542 $1.78.
| HTS code | Description | 2025 value |
|---|---|---|
| 2937 | Hormones & related compounds (incl. GLP-1 analogues and prostaglandins) | $56.3B |
| 3002 | Immunological products & biologics (human blood fractions, vaccines, antisera, monoclonal antibodies) | $28.6B |
| 3004 | Finished pharmaceutical medicaments (packaged for retail or therapeutic use) | $13.6B |
| 9801 | US goods returned without advancement (often testing, QA, supply chain routing) | $6.1B |
| 9021 | Orthopaedic appliances, artificial body parts and implants | $5.6B |
| 2934 / 2933 | Nucleic acids and nitrogen heterocyclic compounds (advanced pharma intermediates) | $8.2B combined |
| 9018 | Medical, surgical, dental and veterinary instruments and appliances | $3.5B |
| 3302 | Mixtures of odoriferous substances (industrial chemical mixtures, specialty compounds) | $2.4B |
| 8542 | Electronic integrated circuits and microassemblies | $1.8B |
HTS 2937 alone is larger than the total goods trade between Ireland and the US in 2015 ($39.4B) or any earlier year. The category barely registered in Ireland’s export data before 2020: It stood below $20 million in 2019, reached $3.1 billion in 2020, $7.9 billion in 2023, $15.4 billion in 2024 and then $56.3 billion in 2025. The step change reflects the scaling of GLP-1 diabetes and obesity drug manufacturing in Ireland.
HTS 3002 (biologics) tells a different story: It grew steadily through the 2010s and reached $38.1 billion in 2024 before falling to $28.6 billion in 2025. Part of this reflects some reclassification of GLP-1-adjacent products into HTS 2937, and part reflects a pandemic-era base effect unwinding.
US customs district routing: Chicago dominance
The Chicago customs district handled $73.1 billion of the $133.5 billion total – 54.7% of all Ireland-origin goods imports into the US in 2025. That single district received more Ireland-origin goods than all other US districts combined. The next nine districts each sit between $3.4 billion and $7.0 billion, in a narrow cluster that largely reflects specific pharmaceutical distribution routing rather than broader trade diversification.
Source: USITC DataWeb, full-year 2025. Exact values (USD billions): Chicago IL $73.11, Savannah GA $6.96, New Orleans LA $6.54, New York NY $6.47, Philadelphia PA $5.63, Wilmington NC $5.57, San Juan PR $5.34, Cleveland OH $5.17, Tampa FL $4.22, Detroit MI $3.45. For reference, Los Angeles CA is at $1.87B (#11) and Houston TX is outside the top 15.
- Air freight logistics: Chicago’s dominance reflects O’Hare’s role as the principal cold-chain air cargo gateway for pharmaceutical shipments from Ireland. Temperature-controlled pharma products fly in volume, and O’Hare is the infrastructure that handles them.
- Midwest routing aligned with headquarters locations: The Chicago flow is consistent with Eli Lilly’s Indianapolis headquarters and the associated Midwest distribution infrastructure. Ireland-made Mounjaro and Zepbound (tirzepatide) travel this route.
- Southern and mid-Atlantic container routing: Savannah, New Orleans, Wilmington NC, San Juan, Tampa and Cleveland are consistent with containerised finished pharmaceutical distribution networks, each serving specific downstream distribution geographies.
Likely corporate drivers
US customs data does not identify importers by name. The product mix, routing patterns and publicly documented Irish manufacturing footprints, however, support strong inferences about which multinational companies drive the majority of flows.
| Company | Product signature | Routing signal |
|---|---|---|
| Eli Lilly | GLP-1 (tirzepatide – Mounjaro/Zepbound), biologics; strong HTS 2937 and 3002 presence | Midwest/Chicago routing; Kinsale (Cork) since 1978 and Limerick manufacturing sites |
| Pfizer | Finished dose; broad HTS 3004 presence | Strong East Coast routing; long-established Irish manufacturing footprint |
| Merck / MSD | Balanced API and finished products; HTS 2933/2937 activity | Mixed East Coast routing; Carlow and Ballydine (Tipperary) sites |
| AbbVie | Concentrated in 293x heterocyclic chemistry; specialised product mix | Sligo manufacturing and related operations |
| Novo Nordisk | GLP-1 (semaglutide – Ozempic/Wegovy); HTS 2937 and 3004 relevance | Athlone (former Alkermes plant, acquired late 2023) now in ramp-up |
| Abbott & MedTech cluster | HTS 9018/9021 medical device exports; diagnostics and implants | Smaller relative to pharma but steady; Galway medtech cluster |
Company attributions above are inferences based on product category signatures, routing patterns and publicly available information about Irish manufacturing operations. They are analytical framing, not confirmed trade data. Actual corporate breakdowns may differ from these estimates.
Strategic implications
Three structural observations follow directly from the 2025 data:
- Trade is highly concentrated in a small number of HTS headings. Three categories (2937, 3002, 3004) account for roughly three-quarters of the total. Adding 2933/2934 and 9021 brings the pharma-and-medical-device share above 90%.
- A narrow set of pharmaceutical multinationals likely accounts for the majority of flows. The product mix and district routing signal a small number of dominant importers behind the customs data.
- The annual total is now sensitive to the timing of US policy actions. The 2025 monthly cadence shows that import volumes can be compressed into narrow windows when tariff deadlines loom. This affects not just the level but the volatility of quarterly trade data.
From these, the strategic questions for Ireland sharpen along several axes:
- US drug pricing and Section 232: The April 2026 Section 232 outcome capped EU pharmaceutical tariffs at 15% (with 0% for companies in MFN pricing/onshoring agreements, which includes Pfizer, Lilly, MSD, Novo Nordisk and AstraZeneca among others). The March and September 2025 shipping spikes reflect the expectation of less favourable outcomes and demonstrate how much value can be front-loaded when needed. Future policy changes could trigger similar patterns.
- US pharmaceutical demand durability: GLP-1 drugs are in a phase of extraordinary growth. Whether this sustains or peaks will shape Ireland’s goods export trajectory over the next five years.
- FDA regulatory cycles: Approval timelines for GLP-1 variants, next-generation biologics and biosimilars will partly determine whether Ireland’s manufacturing capacity utilisation remains at peak levels or moderates.
- Concentration risk: The single-district, single-category, small-number-of-firms structure of the trade means that Ireland’s fiscal exposure to decisions made by a handful of pharmaceutical multinationals is structurally significant. Diversification is a multi-year industrial policy project, not a near-term rebalancing.
Data source
USITC DataWeb – General imports of Ireland-origin goods into the United States, general customs value, HTS 4-digit headings, annual and monthly series. 2025 full-year and 2024 comparative data used throughout. Monthly January 2026 figure from US Census Bureau trade in goods with Ireland.
dataweb.usitc.gov · census.gov/foreign-trade